Evidence map›Paper›PMID 34225744›Full record

ArticleJournal of nanobiotechnology2021

Amplified antitumor efficacy by a targeted drug retention and chemosensitization strategy-based "combo" nanoagent together with PD-L1 blockade in reversing multidrug resistance.

Weixi Jiang, Lei Su, Meng Ao, Xun Guo, Chen Cheng, Yuanli Luo, Zhuoyan Xie, Xingyue Wang, Junrui Wang, Shuling Liu and 6 more

Open access · goldAbstract read
In one paragraph

Article in Journal of nanobiotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 40 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Multidrug Resistance: Are We Still Afraid of the Big Bad Wolf.Pharmaceuticals (Basel, Switzerland) · 2025
    Review
  5. Application of nanomedicines in tumor immunotherapy.Journal of molecular cell biology · 2025
    Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Weixi JiangDepartment of Ultrasound, Chongqing Key Laboratory of Ultrasound Molecular Imaging, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, People's Republic of China.
Lei SuDepartment of Ultrasound, Chongqing Key Laboratory of Ultrasound Molecular Imaging, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, People's Republic of China.
Meng AoDepartment of Ultrasound, Chongqing Key Laboratory of Ultrasound Molecular Imaging, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, People's Republic of China.
Xun GuoDepartment of Ultrasound, Chongqing Key Laboratory of Ultrasound Molecular Imaging, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, People's Republic of China.
Chen ChengDepartment of Ultrasound, Chongqing Key Laboratory of Ultrasound Molecular Imaging, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, People's Republic of China.
Yuanli LuoDepartment of Ultrasound, Chongqing Key Laboratory of Ultrasound Molecular Imaging, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, People's Republic of China.
Zhuoyan XieDepartment of Ultrasound, Chongqing Key Laboratory of Ultrasound Molecular Imaging, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, People's Republic of China.
Xingyue WangDepartment of Ultrasound, Chongqing Key Laboratory of Ultrasound Molecular Imaging, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, People's Republic of China.
Junrui WangDepartment of Ultrasound, Chongqing Key Laboratory of Ultrasound Molecular Imaging, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, People's Republic of China.
Shuling LiuDepartment of Radiology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, People's Republic of China.
Yang CaoDepartment of Ultrasound, Chongqing Key Laboratory of Ultrasound Molecular Imaging, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, People's Republic of China.
Pan LiDepartment of Ultrasound, Chongqing Key Laboratory of Ultrasound Molecular Imaging, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, People's Republic of China.
Zhigang WangDepartment of Ultrasound, Chongqing Key Laboratory of Ultrasound Molecular Imaging, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, People's Republic of China.
Haitao RanDepartment of Ultrasound, Chongqing Key Laboratory of Ultrasound Molecular Imaging, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, People's Republic of China.
Zhiyi ZhouDepartment of General Practice of Chongqing General Hospital, University of Chinese Academy of Sciences, Chongqing, 401147, People's Republic of China. zzy16966@163.com.
Jianli RenDepartment of Ultrasound, Chongqing Key Laboratory of Ultrasound Molecular Imaging, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, People's Republic of China. renjianli@cqmu.edu.cn.ORCID http://orcid.org/0000-0003-1276-780X
Dalian Medical University · CNFirst People's Hospital of Chongqing · CN

Funding

Chongqing Science and Health Joint Medical Research Project-Young and Middle-aged High-level Talent Project 2020GDRC011Fundamental Research Funds for the Key Research Program of Chongqing Science and Technology Commission cstc2019jcyj-zdxmX0020High-level Medical Reserved Personnel Training Project of Chongqing, Kuanren Talents Program of the Second Affiliated Hospital of Chongqing Medical University KR2019G001National Natural Science Foundation of China 31630026National Natural Science Foundation of China 81630047National Natural Science Foundation of China 81873901National Natural Science Foundation of China 81971633
6 · The paper itself

Abstract

backgroundRecent studies have demonstrated that multidrug resistance (MDR) is a critical factor in the low efficacy of cancer chemotherapy. The main mechanism of MDR arises from the overexpression of P-glycoprotein (P-gp), which actively enhances drug efflux and limits the effectiveness of chemotherapeutic agents.

resultsIn this study, we fabricated a "combo" nanoagent equipping with triple synergistic strategies for enhancing antitumor efficacy against MDR cells. Tumor homing-penetrating peptide endows the nanosystem with targeting and penetrating capabilities in the first stage of tumor internalization. The abundant amine groups of polyethylenimine (PEI)-modified nanoparticles then trigger a proton sponge effect to promote endo/lysosomal escape, which enhances the intracellular accumulation and retention of anticancer drugs. Furthermore, copper tetrakis(4-carboxyphenyl)porphyrin (CuTCPP) encapsulated in the nanosystem, effectively scavenges endogenous glutathione (GSH) to reduce the detoxification mediated by GSH and sensitize the cancer cells to drugs, while simultaneously serving as a photoacoustic imaging (PAI) contrast agent for image visualization. Moreover, we also verify that these versatile nanoparticles in combination with PD-1/PD-L1 blockade therapy can not only activate immunological responses but also inhibit P-gp expression to obliterate primary and metastatic tumors.

conclusionThis work shows a significant enhancement in therapeutic efficacy against MDR cells and syngeneic tumors by using multiple MDR reversing strategies compared to an equivalent dose of free paclitaxel.

Indexed as

AnimalsAntineoplastic AgentsB7-H1 AntigenCell Line, TumorCopperDrug Delivery SystemsDrug LiberationDrug Resistance, NeoplasmDrug TherapyFemaleHeterocyclic CompoundsHumansImmune Checkpoint InhibitorsLysosomesMCF-7 CellsMetalloporphyrins5,10,15,20-tetrakis(4-carboxyphenyl)porphinatocopper(II)Antineoplastic AgentsB7-H1 AntigenCopperHeterocyclic CompoundsImmune Checkpoint InhibitorsMetalloporphyrinsOrganophosphorus CompoundsPaclitaxeltris(o-phenylenedioxy)cyclotriphosphazeneChemotherapy enhancementEndo/lysosomal escapeMultidrug resistancePD-L1 blockadeTumor homing-penetrating peptide

Identifiers

PMID34225744
PMCPMC8256488
OpenAlexW3164381262

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.